Evotec
Evotec SE, a leading global biotechnology company headquartered in Germany, is renowned for its innovative drug discovery and development solutions. Founded in 1993, Evotec has established a strong presence in Europe, North America, and Asia, focusing on areas such as central nervous system disorders, metabolic diseases, and oncology. The company offers a unique platform that integrates cutting-edge technologies and extensive expertise, enabling efficient and effective drug development processes. Notable achievements include strategic partnerships with major pharmaceutical firms, positioning Evotec as a key player in the biopharmaceutical industry. With a commitment to advancing healthcare, Evotec continues to drive progress in the development of novel therapeutics, making significant contributions to the global fight against disease.
DitchCarbon Score
How does Evotec's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Evotec's score of 67 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Evotec's reported carbon emissions
In 2023, Evotec SE reported total greenhouse gas emissions of approximately 299,948,000 kg CO2e. This includes 15,720,000 kg CO2e from Scope 1 emissions and 11,554,000 kg CO2e from Scope 2 emissions, while Scope 3 emissions accounted for a significant 272,674,000 kg CO2e. Evotec has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 emissions by at least 50.4% by 2032, using 2021 as the baseline year. Additionally, the company plans to achieve net-zero emissions across all scopes by 2045. For Scope 3 emissions, Evotec targets a reduction of 72% per million EUR value added by 2032. Furthermore, the company is committed to increasing its sourcing of renewable electricity from 25% in 2021 to 100% by 2026, maintaining this level through 2030. These targets align with the Science Based Targets initiative (SBTi) and reflect Evotec's commitment to sustainable practices within the pharmaceuticals, biotechnology, and life sciences sector. The company also aims for 80% of its suppliers, by emissions, to have science-based targets by 2027, reinforcing its dedication to reducing its overall carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 28,000 | 00,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Evotec is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
